Novartis BioCamp 2011
Today's nicest young talent will soon be changing the world. Novartis Ecumenical Biotechnology Leadership Camp (BioCamp) offers top ...
NOVARTIS@CEP
Healthcare - where are we headed?
" diabetes cholesterol "fundamentals attack" stroke Alzheimer's Alzheimers COPD Novartis NVS "Novartis AG" Sandoz " ...
Novartis cleared to market two drugs in Japan
Tuesday said it has received regulatory sanction in Japan for once-daily Gilenya (fingolimod) for the prevention of reversion and delay of progression of physical disability in adults with multiple sclerosis, and for Illaris(canakinumab) subcutaneous injection, the first treatment for adults and children with cryopyrin-associated periodical syndrome (CAPS).MAIN FACTS:
- In the US, Gilenya is approved for relapsing forms of MS. In the EU, Gilenya is approved for people with hugely active relapsing-remitting MS despite treatment with beta interferon, or in patients with in a wink evolving severe relapsing-remitting MS.
- The Ilaris agreement is also extended to include all CAPS disease phenotypes: familial undemonstrative auto-inflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS) and neonatal-sally multisystem inflammatory disease (NOMID).
- "Today's report demonstrates our continued commitment to bringing innovative new treatments to patients where there is signal unmet need," said David Epstein, Steer of the Pharmaceuticals Division of Novartis.
Novartis invests $24M in Proteus Biomedical | mobihealthnews
Pharmaceutical giant Novartis announced that would invest $24M in upfront cash and equity as part of an exclusive worldwide agreement for the pharma company to license Proteus Biomedical’s sensing technology for organ transplantation. (That must be the kind of exclusive deal Novartis had in mind when the two companies announced their collaboration on a pilot last year.)
As part of the deal, Novartis also has “certain” options rights related to oncology, cardiovascular, and clinical development. To date, Proteus has focused on cardiovascular disease, tuberculosis and psychiatric disorders applications for its technology, which is currently undergoing clinical investigation.
Last September Novartis tapped Proteus for a small 20 patient study to track patients’ compliance with their blood pressure drug regimen. The patients took blood pressure drug Diovan and the study organizers tracked their compliance via Proteus’ “chip in the pill” technology, which reports to a receiver sensor on the patient’s shoulder when the medication has been ingested. The study improved compliance from 30 percent to 80 percent after six months, according to Novartis.
“We believe that Novartis is a global leader in organ transplant drug development and marketing, which makes it an excellent collaborator to advance sensor-based pharmaceutical treatment systems,” Andrew Thompson, president and CEO, Proteus said in a statement. “We have a great opportunity together to bring a new type of pharmaceutical product to market that could aid patients, their families and physicians to attain maximum adherence with pharmaceutical therapy.”
This is not the first time we have written about the import of medical adherence for organ transplants — just last year Mt. Sinai discussed its pilot program with wireless health start-up Carespeak , which offers text message reminders for medication adherence:
...Novartis - News
|
Novartis receives FDA nod for Gleevec drug label change The US Bread and Drug Administration (FDA) has approved Novartis Gleevec (imatinib mesylate) tablets mark recommending 36 months of treatment for KIT (CD117)-encouraging gastrointestinal stromal tumors (GIST) patients after surgery.Novartis wins expanded Marrow use for Gleevec; Takeda cuts outlook as Astellas FDA approves Novartis upper Glivec(R) label recommending extending treatment to FDA approves Novartis stupefy Glivec® label recommending extending treatment to - -all 50 advice articles » |
|
Shareholder group slams Novartis over chairman pay By Katharina Bart | ZURICH Feb 2 () - Shareholder assemble Ethos said Novartis investors should vote against re-electing council members in charge of allotting bonus pay to the Swiss drugmaker's chairman, Daniel Vasella. The call is part of an bout |
|
Novartis Vaccines & Diagnostics Selects GlobalEnglish Corporation as Its ... Novartis Vaccines & Diagnostics Selects GlobalEnglish Corporation as Its GlobalEnglish.com ), the unequalled provider of on-demand software to advance Enterprise Grace for global organizations, today announced that it has been selected by Novartis Vaccines & Diagnostics, the beget's fifth-largest vaccines manufacturer and and more » |
Novartis Issues Warning for Pet Products
RTT NewsNovartis Carnal Health cautions pet owners that foreign tablets may be found in incontestable bottles of their Clomicalm tablets. The company issued the advice to veterinarians and clinics as a precautionary measure, more than two weeks after its consumer Novartis issues aware to veterinarians regarding ClomicalmNovartis Warns Of Wrong Tablets In Pet Pharmaceutical Clomicalm Bottlesall 3 news articles »
|
|
Novartis CEO Looks to Mitigate Currency Risk By STEN STOVALL LONDON—Currency volatility will be a truth of life for at least the next five years and companies need to prepare strategies for protecting themselves against that chance, said Novartis AG Chief Executive Joe Jimenez.and more » |
FDA report details issues at Novartis' Neb. plant
DigitalJournal.comFDA despatch details issues at Novartis' Neb. plant(AP) — A new FDA account says Novartis was slow to address problems at its Lincoln, Neb., manufacturing informer that is at the center of a nationwide recall of over-the-counter drugs. The Jan. 20 inspection article, obtained by the Lincoln Journal Star Most-recent FDA communication sheds light on Novartis shutdown, recallNovartis Pharma: pre-eminent drugs recallFDA Report Details Issues At Novartis' Lincoln Plantall 16 intelligence articles »
|
The Zacks Analyst Blog Highlights: Pfizer, Biogen Idec, Elan, Novartis and Roche
Proactive Investors USA & Canada(NYSE: ELN), Novartis (NYSE: NVS) and Roche (OTC: RHHBY). Pfizer Inc. (NYSE: PFE) posted fourth barracks earnings of 50 cents per share, 3 cents above the Zacks Consensus Guesstimate and the year-ago earnings of 47 cents. Revenues, however, mow down 4% to Biogen & Elan Announce Tysabri Judicial proceeding - Analyst BlogBiogen Q4 Seen Rising, As Its MS Drugs Ambition Stockall 105 news articles »
|
